ClinicalTrials.Veeva

Menu
R

Research Carolina Elite | Denver, NC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

TAK-861
AD109
Astegolimab
TAK-994
Pitolisant
Pomotrelvir
Deudomperidone
PBI-0451
BRII-296
CIN-102

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 21 total trials

A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients with Idiopathic Hypersomnia

The primary objective of this study is to assess the long-term safety and effectiveness of pitolisant in patients with idiopathic hypersomnia (IH) wh...

Active, not recruiting
Idiopathic Hypersomnia
Excessive Daytime Sleepiness
Drug: Pitolisant

The main aim is to evaluate the safety and tolerability of TAK-861 on participants with type 1 narcolepsy, who were exposed to previously tested dose...

Enrolling
Narcolepsy Type 1
Drug: TAK-861

The primary purpose of the study is to assess the effect of lorundrostat taken orally (po) once a day on the Apnea-Hypopnea Index (AHI) in participan...

Enrolling
Hypertension
Obstructive Sleep Apnea
Drug: Placebo
Drug: Lorundrostat

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Enrolling
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Astegolimab
Drug: Placebo

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling
Diabetic Gastroparesis
Drug: Placebo
Drug: CIN-102 Dose 15mg or 10mg

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Astegolimab

The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus peglot...

Active, not recruiting
Gout
Drug: Methotrexate
Biological: Pegloticase

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obs...

Active, not recruiting
OSA
Drug: AD109
Drug: Placebo

Trial sponsors

Takeda logo
Apnimed logo
Amgen logo
H
Roche logo
Brii Biosciences logo
C
Eisai logo
M
P

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems